J Cancer 2018; 9(6):998-1005. doi:10.7150/jca.22915
IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Roentgena 5, 02-781 Warsaw, Poland
2. Early Phase Clinical Trials Unit, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Roentgena 5, 02-781 Warsaw, Poland
3. Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Roentgena 5, 02-781 Warsaw, Poland
4. Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Roentgena 5, 02-781 Warsaw, Poland
5. Department of Pathology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Roentgena 502-781 Warsaw, Poland
# Equal contribution
Lugowska I, Teterycz P, Mikula M, Kulecka M, Kluska A, Balabas A, Piatkowska M, Wagrodzki M, Pienkowski A, Rutkowski P, Ostrowski J. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. J Cancer 2018; 9(6):998-1005. doi:10.7150/jca.22915. Available from http://www.jcancer.org/v09p0998.htm
Background. Recent studies have shown that isocitrate dehydrogenase 1/2 (IDH1/2)- activating mutations occur in a variety of cancers, including acute myeloid leukaemia, gliomas, and chondrosarcomas (CHS)s. The effect of IDH1/2 mutation on overall survival (OS) has not been reported in CHS. The aim of our study was to assess the prevalence of known cancer-related gene mutations in CHS, as well as their prognostic role in patient survival.
Methods. DNA from FFPE samples of 80 patients (F:M- 1:1.3; mean age: 58 years; range 27-86) with histologically confirmed CHS (G1:29; G2:34; G3:17) was subjected to library preparation with the Ion AmpliSeq Cancer Hotspot Panel v2 and sequenced on the PGM Ion Torrent.
Results. Among the clinical features only histological grade influenced OS. Deep sequencing identified 1784 single nucleotide variants. Of them, 426 were considered to be pathogenic or probably pathogenic. Activating IDH1/2 mutations were found in 27 patients (34%) including 17 R132 IDH1 (21%), 10 R172 IDH2 (13%) and 3 R140 IDH2 variants (4%). Three patients had concurrent IDH1 and IDH2 mutations. The R140 IDH2 mutant has not been reported to date in CHS patients. OS for CHS patients with IDH1/2 mutations was significantly lower than in patients without mutations (93% vs 64%; p<0.001). No other genetic feature of the Cancer Hotspot Panel had an impact on OS.
Conclusions. In CHS, IDH1/2-mutation status and the histological aggressiveness of the CHS are important predictors for OS. The R140 IDH2 may also be a novel target for the treatment of CHS patients.
Keywords: chondrosarcoma, IDH1/2 mutation, AmpliSeq Cancer Hotspot Panel, next-generation sequencing